Sima Porten
@SimaPorten
Followers
2K
Following
2K
Media
18
Statuses
554
🎉 Attention #OncFellowship applicants! Join us at #SUO25 in Phoenix, Dec 2-5, 2025 & learn about the UCSF UroOnc Fellowship Program. Complete the link below to meet our Program Director, Dr. Sima Porten: https://t.co/4m1k2kqODJ See you there!
0
3
4
Mesa redonda sobre CVNMI: expertos nac. e internac. revisaron casos clínicos en los que abordaron distintas presentaciones del cáncer de vejiga. Además, compararon las experiencias en distintos centros. Aspecto destacado: opciones terapia intravesical. #CongresoCentenarioSCHU
1
3
4
@BladderCancerUS @NatureComms Huge thanks to @BladderCancerUS and @BCAN_Research for the YIA+support, amazing med student Kevin Chang & awesome mentors+collaborators @CChuMD @koshkin85 @corynnkasap @felixfengmd @apwiita @DrTFriedlander @SimaPorten @DSolit @DrRosenbergMSK @jklee_lab @UCSFUrology @UCSFCancer
0
3
11
Bladder cancer variants share aggressive features including a CA125+ cell state and targetable TM4SF1 expression | Nature Communications
nature.com
Nature Communications - Single cell analysis of histologic variant bladder tumors detects a shared CA125+ tumor cell state associated with aggressive clinical features and reveals enriched...
1
12
48
Just published online in @JCO_ASCO : #SunRISe1 Phase IIb results show TAR-200 (novel intravesical drug releasing system) achieves 82.4% CR in BCG-unresponsive high-risk NMIBC—with durable responses (median DOR 25.8 mo) & low toxicity. A game-changer for pts with #NMIBC.
ascopubs.org
PURPOSETAR-200 is a first-in-class intravesical drug-releasing system designed to provide sustained delivery of gemcitabine in the bladder. TAR-200 alone or in combination with cetrelimab (PD-1...
5
50
163
So thrilled to stay in the Bay to continue the research momentum I’ve built. Thanks to @pcarroll_ @SimaPorten @Uro_Max @haognguyen @dr_coops @SamWashUro @anobelodisho @CChuMD @MeeraChappidi for the support!
Congrats to Kevin Shee for matching into the UCSF UroOnc SUO fellowship program! @KShee11
#UroOnc #SUO #SUOMatch
2
5
41
The International Bladder Cancer Group (IBCG) is pleased to announce the #IBCG2025 Travel Award, designed to support outstanding fellows and early-career academic faculty who are committed to advancing the field of bladder cancer. For more information and to apply:
4
18
50
UCSF BCAN community really showed up for our walk this year, babies and 4 legged friends alike, to support our patients with bladder CA and raising $40k for research. No one walks alone 🧡@bcan_chisolm @UCSFCancer @UCSFUrology
@SimaPorten @jonchou05 @koshkin85 @SamWashUro
0
4
17
Amazing time at #eau25 Madrid! Outstanding scientific program & great catching up w everyone! @SimaPorten @spsutkaMD @bjartell @JimCatto @shilpaonc @Caba_L @AStenzl @RenuEapen @carme_mir1 @GSK_UofT @CathyJPierce @DrJohnSfakianos @DrShariat @Tilki_De @mishabeltran @SumeetBhanvadia
1
6
50
How amazing to be lecturing on urologic oncology in Argentina with my college best friend @SimaPorten 🙏🏼 If you told me this 20 years ago I never would have believed it! Thanks @DrVitagliano @PabloNContreras for the invitation! #ILookLikeAUrologist #O&EHA2024 🇦🇷
2
2
46
The most inspirational talk I have heard in a long time. You can make a difference! Tell the people you love that they matter everyday! #WorldGU24
Get ready to be inspired! 🌟 Join @JOLearyInspires, two-time bestselling author of On Fire and In Awe, at 5:00 PM for an unforgettable Keynote Speaker session at #WorldGU24. Hear his incredible story of resilience and triumph. #liveinspired
1
3
24
Congratulations to the @BladderCancerUS innovation award winners !
We are so proud to announce the recipients of the BCAN 2024 Research Innovation Awards, @FaltasLab of @WeillCornell and @ResearchWyatt of @UBC. We encourage you to read more about their innovative proposals here: https://t.co/2q8aSCMmRL. Congratulations Drs. Faltas and Wyatt!
1
3
10
The NTACT residual disease test, eloquently presented by @scientistatlrge published in @JCOPO_ASCO. .Remarkably, over 50% of patients without visible residual disease had positive mutations, indicative of field cancerization—mutations present in adjacent normal tissue WITHOUT
2
14
41
The IBCG Quick Guide to Non-Muscle Invasive Bladder Cancer (NMIBC) Bladder Cancer Quick Reference Sheet summarizes essential details on diagnosis, treatment options, and follow-up for NMIBC all in one convenient place #AUA24 #EAU24 #IBCG24 #ASCO24 Designed by @AmandaMyersMD
13
157
354
No one walks alone! The BCAN community @UCSFUrology is strong. Honored to have Diane Quale here with us for the annual walk. @SimaPorten @mvankuikenmd @ben_breyer @SamWashUro @koshkin85
0
6
26
Good day for #bladdercancer BOND-3 results presented by @MarkTysonMD showing 75.2% CR at anytime for pts with BCG unresponsive disease. Over half of non responders converted to CR with repeat dosing. 96.7% PFS@12 mos. More trials to come through @UroOnc @UrogerliMD @cgoncology
1
9
48
@SimaPorten @UCSFUrology presents Ph III SUNRISE 5 trial on papillary only BCG unresponsive NMIBC - evaluating TAR-200 vs intravesical chemotherapy now open and enrolling globally 👏🏼
0
2
14
Appreciate @urotoday featuring our @UCSFCancer study of FAP-targeted imaging in #BladderCancer with @thomashopemd @SimaPorten Vipul Kumar Important step for new imaging modalities to better stage this disease @UCSFUrology @UCSFimaging @BladderCancerUS 👇 https://t.co/GUWfVTmfdd
0
5
13
💫Immensely proud of our @UCSFUrology fellows, residents, students, and visiting students for their impressive presence at #AUA24! 💫 👀 Please look out for these amazing individuals - we'll be sharing reminders along the way!
3
6
32